3月12日，据CDE官网消息，百奥泰生物制药股份有限公司联合申请药品“BAT1308注射液”，获得临床试验默示许可，受理号CXSL2300906。
公示信息显示，药品“BAT1308注射液”适应症：拟联合注射用BAT8008用于治疗晚期实体瘤患者。
百奥泰生物制药股份有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.